| P50 | author | Kevin K W Wang | Q37837051 |
| | Stefania Mondello | Q47504595 |
| | Firas Kobeissy | Q56989716 |
| P2093 | author name string | Jackson Streeter | |
| | Ronald L Hayes | |
| | Richard Rubenstein | |
| | Zhiqun Zhang | |
| P2860 | cites work | Clinical trials in head injury | Q24543977 |
| | Classification of traumatic brain injury for targeted therapies | Q24656273 |
| | Neuroprotection targets after traumatic brain injury | Q28273906 |
| | A panel of neuron-enriched proteins as markers for traumatic brain injury in humans | Q33657708 |
| | Validation of serum markers for blood-brain barrier disruption in traumatic brain injury | Q33657728 |
| | alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury | Q33766805 |
| | P43/pro-EMAPII: a potential biomarker for discriminating traumatic versus ischemic brain injury | Q33772594 |
| | Peripheral markers of brain damage and blood-brain barrier dysfunction | Q33789473 |
| | Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats | Q33793699 |
| | Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study | Q33995697 |
| | Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage | Q34093020 |
| | αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients | Q34142573 |
| | Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury | Q34193737 |
| | Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality | Q34222299 |
| | Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. | Q34263891 |
| | Proteomics in neuroscience: from protein to network. | Q34405066 |
| | Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. | Q34545408 |
| | Application of proteomics technology to the field of neurotrauma | Q35153256 |
| | Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. | Q35552700 |
| | Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study | Q35558386 |
| | Systems biology in neuroscience: bridging genes to cognition. | Q35589903 |
| | Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients | Q35876807 |
| | Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss | Q36129196 |
| | Proteomic identification of biomarkers of traumatic brain injury. | Q36227974 |
| | Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury | Q36242794 |
| | Detection of brain injury by fatty acid-binding proteins | Q36275438 |
| | Structures in systems biology | Q36851656 |
| | The cost of cerebral ischaemia. | Q37198081 |
| | Blood biomarkers in the diagnosis of ischemic stroke: a systematic review | Q37227913 |
| | Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention | Q37316677 |
| | The development of stroke therapeutics: promising mechanisms and translational challenges | Q37325124 |
| | Biomarkers of blast-induced neurotrauma: profiling molecular and cellular mechanisms of blast brain injury. | Q37473431 |
| | Inflammatory mechanisms in ischemic stroke: therapeutic approaches | Q37634142 |
| | Novel biomarkers in cardiovascular disease: update 2010. | Q37799113 |
| | Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation | Q37817168 |
| | How to make better use of thrombolytic therapy in acute ischemic stroke | Q37889116 |
| | Use of biomarkers for diagnosis and management of traumatic brain injury patients | Q38089787 |
| | Serum biomarker concentrations and outcome after pediatric traumatic brain injury | Q40140762 |
| | Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis | Q43226789 |
| | Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study | Q44278432 |
| | Proteins released from degenerating neurons are surrogate markers for acute brain damage | Q44933188 |
| | Glial fibrillary acidic protein is highly correlated with brain injury | Q45148657 |
| | Novel surrogate markers for acute brain damage: cerebrospinal fluid levels corrrelate with severity of ischemic neurodegeneration in the rat. | Q46497516 |
| | Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry | Q46532753 |
| | Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. | Q46618995 |
| | Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers | Q46688898 |
| | Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility | Q47289795 |
| | Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury | Q47689828 |
| | Serum markers of brain damage and outcome prediction in patients after severe head injury | Q48109541 |
| | Early Biomarkers of Stroke | Q48193653 |
| | Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury | Q48233639 |
| | Morphologic and biochemical characterization of brain injury in a model of controlled blast overpressure exposure | Q48278372 |
| | Novel differential neuroproteomics analysis of traumatic brain injury in rats | Q48487232 |
| | C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome | Q48530314 |
| | S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke | Q48613065 |
| | Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool | Q48665895 |
| | Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats | Q48770448 |
| | PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke | Q48788452 |
| | Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke | Q48822422 |
| | Neuron-specific enolase as an aid to outcome prediction in head injury | Q48899704 |
| | Value of biomarker-based diagnostic test in differential diagnosis of hemorrhagic-ischemic stroke. | Q49065289 |
| | GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome | Q49090833 |
| | A novel marker for traumatic brain injury: CSF alphaII-spectrin breakdown product levels | Q49110696 |
| | Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. | Q51743594 |
| | Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. | Q53602150 |
| | Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury | Q71698502 |
| | Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein | Q73149965 |
| | Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation | Q73632997 |
| | Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings | Q74265433 |
| | Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain | Q79399119 |
| | Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice | Q80079870 |
| | Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury | Q80914178 |
| | Neurofilament and glial fibrillary acidic protein in multiple sclerosis | Q80980689 |
| | Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children | Q81115112 |
| | Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model | Q81458900 |
| | Cerebral microdialysis of interleukin (IL)-1beta and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats | Q82713175 |
| P433 | issue | 4 | |
| P921 | main subject | biomarker | Q864574 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 455-462 | |
| P577 | publication date | 2011-12-07 | |
| P1433 | published in | Translational stroke research | Q26842494 |
| P1476 | title | Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside | |
| P478 | volume | 2 | |